Laboratory of Clinical Pharmacology
|
John Kane, MD |
For over 30 years, Dr. Kane has been developing and advancing new treatments for psychiatric conditions. He delivers on the model of translational research with a long history of clinical trials, most notably his groundbreaking work with clozapine for patients with treatment-resistant schizophrenia that was conducted in the 1980s. He has always been on the forefront of bringing the next generation of medicines to patients while maintaining his focus on improving symptoms, reducing side effects and enhancing long-term quality of life.
The laboratory runs a number of clinical trials. Dr. Kane also devotes his efforts to standardizing the outcome measurements in psychiatric research. Since the beginning of his residency at The Zucker Hillside Hospital in Glen Oaks in 1971, Dr. Kane has committed his career to unraveling the mysteries of this brain disorder. He pioneered studies on patients hospitalized for the first time showing florid symptoms such as hallucinations and delusions.
The program, under the direction of Dr. Kane, also conduct pioneering studies on first episode schizophrenia. Dr. Kane and his colleagues helped determine treatment strategies for relapse prevention and management of treatment refractory patients. His findings have been circulated worldwide and have become part of the fabric of modern care. All of the scientists within the Center work in collaboration with Dr. Kane on the clinical pharmacology studies underway at the Zucker Hillside Hospital. He is the Principal Investigator on two large federal grants.
Scientific Investigators/Collaborators:
Alan Mendelowitz, MD
Serge Sevy, MD
Selected Publications:
Szeszko PR. Robinson DG. Sevy S. Kumra S. Rupp CI. Betensky JD. Lencz T. Ashtari M. Kane JM. Malhotra AK. Gunduz-Bruce H. Napolitano B. Bilder RM. Anterior cingulate grey-matter deficits and cannabis use in first-episode schizophrenia. British Journal of Psychiatry. 190:230-6, 2007.
Leucht S. Busch R. Kissling W. Kane JM. Early prediction of antipsychotic nonresponse among patients with schizophrenia. Journal of Clinical Psychiatry. 68(3):352-60, 2007.
Correll CU. Frederickson AM. Kane JM. Manu P. Does antipsychotic polypharmacy increase the risk for metabolic syndrome? Schizophrenia Research. 89(1-3):91-100, 2007.
Kobak KA. Kane JM. Thase ME. Nierenberg AA. Why do clinical trials fail? The problem of measurement error in clinical trials: time to test new paradigms? Journal of Clinical Psychopharmacology. 27(1):1-5, 2007.
Kane JM. Meltzer HY. Carson WH Jr. McQuade RD. Marcus RN. Sanchez R. Aripiprazole Study Group. Aripiprazole for treatment-resistant schizophrenia: results of a multicenter, randomized, double-blind, comparison study versus perphenazine. Journal of Clinical Psychiatry. 68(2):213-23, 2007.
Hodgkinson CA. Goldman D. Ducci F. DeRosse P. Caycedo DA. Newman ER. Kane JM. Roy A. Malhotra AK. The FEZ1 gene shows no association to schizophrenia in Caucasian or African American populations. Neuropsychopharmacology. 32(1):190-6, 2007.
DeRosse P. Hodgkinson CA. Lencz T. Burdick KE. Kane JM. Goldman D. Malhotra AK. Disrupted in schizophrenia 1 genotype and positive symptoms in schizophrenia. Biological Psychiatry. 61(10):1208-10, 2007.
Cornblatt BA, Lencz T, Smith CW, Olsen R, Auther A, Nakayama E, Lesser M, Tai J, Shah M, Foley C, Kane JM, Correll CU. Can antidepressants be used to treat the schizophrenia prodrome? Results of a prospective, naturalistic treatment study. J Clin Psychiatry. 68(4):546-57, 2007.
Gunduz-Bruce H, Narr KL, Gueorguieva R, Toga AW, Szeszko PR, Ashtari M, Robinson DG, Kane JM, Bilder RM. CSF sub-compartments in relation to plasma osmolality in healthy controls and in patients with first episode schizophrenia. Psychiatry Research. 155(1):57-66, 2007.
Correll CU. Penzner JB. Frederickson AM. Richter JJ. Auther AM. Smith CW. Kane JM. Cornblatt BA. Differentiation in the preonset phases of schizophrenia and mood disorders: evidence in support of a bipolar mania prodrome. Schizophrenia Bulletin. 33(3):703-14, 2007.
Lasser RA, Bossie CA, Locklear JC, Zhu Y, Kane JM. Long-acting risperidone in young adults with early schizophrenia or schizoaffective illness. Annals of Clin Psychiatry. 19(2):65-71, 2007.
Lencz T, Morgan TV, Athanasiou M, Dain B, Reed CR, Kane JM, Kucherlapati R, Malhotra AK. Converging evidence for a pseudoautosomal cytokine receptor gene locus in schizophrenia. Mol Psychiatry. 12(6):572-80, 2007.
Helldin L, Kane JM, Karilampi U, Norlander T, Archer T. Remission in prognosis of functional outcome: a new dimension in the treatment of patients with schizophrenia spectrum disorders. Schiz Res. 93(1-3):160-8, 2007.
Correll CU, Penzner JB, Lencz T, Auther A, Smith CW, Malhotra AK, Kane JM, Cornblatt BA. Early identification and high-risk strategies for bipolar disorder. Bipolar Disorders. 9(4):324-38, 2007.
Szeszko PR, Robinson DG, Sevy S, Kumra S, Rupp CI, Betensky JD, Lencz T, Ashtari M, Kane JM, Malhotra AK, Gunduz-Bruce H, Napolitano B, Bilder RM. Anterior cingulated grey matter deficits in first-episode schizophrenia patients with cannabis use. Brit Journal of Psychiatry. 190:230-6, 2007.
Kane JM. Crandall DT. Marcus RN. Eudicone J. Pikalov A 3rd. Carson WH. Swyzen W. Symptomatic remission in schizophrenia patients treated with aripiprazole or haloperidol for up to 52 weeks. Schizophrenia Research. 95(1-3):143-50, 2007 Sep.
Leucht S. Davis JM. Engel RR. Kane JM. Wagenpfeil S. Defining 'response' in antipsychotic drug trials: recommendations for the use of scale-derived cutoffs. Neuropsychopharmacology. 32(9):1903-10, 2007 Sep.
Gunduz-Bruce H. Szeszko PR. Gueorguieva R. Ashtari M. Robinson DG. Kane JM. Bilder RM. Cortisol levels in relation to hippocampal sub-regions in subjects with first episode schizophrenia. Schizophrenia Research. 94(1-3):281-7, 2007 Aug.
Helldin L. Kane JM. Karilampi U. Norlander T. Archer T. Remission in prognosis of functional outcome: a new dimension in the treatment of patients with psychotic disorders. Schizophrenia Research. 93(1-3):160-8, 2007.
Malhotra JK, Lencz T, Correll CU, Kane JM. Genomics and the future of pharmacotherapy in psychiatry. International review of Psychiatry. 19(5):523-30, 2007
Kane JM. Treatment adherence and long-term outcomes. CNS Spectrums. 12(10 Suppl 17):21-26, 2007
Kane JM. The management of schizophrenia: safety, treatment, and continuity of care. Introduction. CNS Spectrums. 12(10 Suppl 17):4, 2007.
Correll CU, Kane JM. One-year incidence rates of tardive dyskinesia in children and adolescents treated with second-generation antipsychotics. Journal of Child & Adolescent Psychopharmacology. 17(5):647-56, 2007.
Haupt DW, Kane JM. Metabolic risks and effects of atypical antipsychotic treatment. Journal of Clinical Psychiatry. 68(10):e24, 2007.
Bratti IM, Kane JM, Marder SR. Chronic restlessness with antipsychotics. American Journal of Psychiatry. 164(11):1648-54, 2007.
Kane JM. Editorial: Schizophrenia International Research Society. Schizophrenia Bulletin. 33(6):1259, 2007.
Goldberg TE, Goldman RS, Burdick KE, Malhotra AK, Lencz T, Patel RC, Woerner MG, Schooler NR, Kane JM, Robinson DG. Cognitive improvement after treatment with second-generation antipsychotic medications in first-episode schizophrenia: is it a practice effect? Arch Gen Psychiatry. 64(10):1115-22, 2007.
Lencz T, Lambert C, DeRosse P, Burdick KE, Morgan TV, Kane JM, Kucherlapati R, Malhotra AK. Runs of homozygosity reveal highly penetrant recessive loci in schizophrenia. Proceedings of the National Academy of Sciences of the USA, 104(50):19942-7, 2007.
Kane JM. Teaching and practicing psychopharmacology. J Clin Psychiatry. 68(11):1807-8, 2007.
Leucht S, Heres S, Hamann J, Kane JM. Methodological issues in current antipsychotic drug trials. Schiz Bull. 34(2):275-85, 2008.
Kumra S, Kranzler H, Gerbino-Rosen G, Kester HM, DeThomas C, Kafantaris V, Correll CU, Kane JM. Clozapine and “high dose” olanzapine in refractory early-onset schizophrenia: a 12 week randomized and double-blind comparison. Biol Psychiatry.63(5):524-9, 2008.
Strom BL, Faich G, Reynolds RF, Eng SM, Rappard R, Kane JM. The ziprasidone observational study of cardiac outcomes (ZODIAC): Design and baseline subject characteristics. J Clin Psychiatry.69(1):114-21, 2008.
Kane JM, Leucht S. Unanswered questions in schizophrenia clinical trials. Schiz Bull.34(2):302-9, 2008.
Kane JM, Leucht S. Issues in psychopharmacology. Schiz Bull. 34(2)258, 2008.
Zhu B, Ascher-Svanum H, Faries D, Correll CU, Kane JM. Cost of antipsychotic polypharmacy in the treatment of schizophrenia. BMC Psychiatry 8:19, 2008.
Keefe RS. Malhotra AK. Meltzer HY. Kane JM. Buchanan RW. Murthy A. Sovel M. Li C. Goldman R. Efficacy and safety of donepezil in patients with schizophrenia or schizoaffective disorder: significant placebo/practice effects in a 12-week, randomized, double-blind, placebo-controlled trial. Neuropsychopharmacology. 33(6):1217-28, 2008 May.
Kane JM, Lauriello J, Laska E, DiMarino M, Wolfgang C. Long-term efficacy and safety of iloperidone: results from three clinical trials for the treatment of schizophrenia. J Clin Psychoph. 28:S29-S35, 2008
Leucht S, Shamsi SAR, Busch R, Kissling W, Kane JM. Predicting antipsychotic drug response- Replication and extension to six weeks in an international olanzapine study. Schiz Research 101(1-3):312-319, 2008
Szeszko PR, Robinson DG, Ashtari M, Vogel J, Betensky J, Sevy S, Ardekani BA, Lencz T, Malhotra AK, McCormakc J, Miller R, Lim KO, Gunduz-Bruce H, Kane JM, Bilder RM. Clinical and neuropsychological correlates of white matter abnormalities in recent onset schizophrenia. Neuropsychopharmacology. 33(5):976-84, 2008.
Kane JM. Relapse prevention in patients with schizophrenia.J Clin Psychiatry. 69(4):e11, 2008.
Correll CU, Kane JM, Manu P. Identification of high-risk coronary heart disease patients receiving atypical antipsychotics: Single low density-lipoprotein cholesterol threshold or complex national standard? J Clin Psychiatry.69(4):578-83, 2008.
Betensky JD, Robinson DG, Gunduz-Bruce H, Sevy S, Lencz T, Kane JM, Malhotra AK, Miller R, McCormack J, Bilder RM, Szeszko PR. Patterns of stress in schizophrenia. Psychiatry Research. 160(1):38-46, 2008.
Kinon BJ, Chen L, Asher-Svanum H, Stauffer VL, Kollack-Walker S, Sniadecki JL, Kane JM. Predicting response to atypical antipsychotics based on early response in the treatment of schizophrenia. Schiz Research. 102(1-3):230-40, 2008.
Kumra S, Kranzler H, Gerbino-Rosen G, Kester HM, DeThomas C, Kafantaris V, Correll CU, Kane JM. Clozapine and “high dose” olanzapine in refractory early-onset schizophrenia: a 12 week randomized and double-blind comparison. Biol Psychiatry.63(5):524-9, 2008.
Kane JM. Sedation as a side effect of the treatment of mental disorders. J Clin Psychiatry 69(7)e20, 2008.
Kane JM, Perlis RH, Malhotra AK. Clinical insights into pharmacogenetics and schizophrenia, part 2. J Clin Psychiatry 69(6):1006-13, 2008.
Szeszko PR. Hodgkinson CA. Robinson DG. Derosse P. Bilder RM. Lencz T. Burdick KE. Napolitano B. Betensky JD. Kane JM. Goldman D. Malhotra AK. DISC1 is associated with prefrontal cortical gray matter and positive symptoms in schizophrenia. Biological Psychology. 79(1):103-10, 2008.
Kane JM, , Assuncao-Talbott S, Eudicone J, Pikalov A, Whitehead R, Crandall DT. The efficacy of aripiprazole in the treatment of multiple symptom domains in schizophrenia patients: A pooled analysis of data from the pivotal trials. Schizophrenia Research. 105(1-3):208-15, 2008.
Dankert ME, Brensinger CM, Metzger KL, Han C, Gonzalez-Pinto A, Mosquera F, Gayares JG, Li C, Severus WE, Langosch JM, Tateno M, Mihai A, Johnstone EC, MacIntyre DJ, Lallart X, Lallart E, Hoeft F, Wiguna T, Farooq S, Koleva SG, Radoeva PD, Mesen A, Laprade B, Nair SRN, Babb SM, Adler C, Habibpoor E, Belmaker R, Rybakowsi J, Owe-Larsson B, Young A, Malhotra S, Sivakumar, Kane JM, Swanson C, Rush AJ, Siegel SJ. Attitudes towards implantable psychiatric medication in a worldwide sample of patients. Schizophrenia Research. 105(1-3):279-86.
Correll CU. Smith CW. Auther AM. McLaughlin D. Shah M. Foley C. Olsen R. Lencz T. Kane JM. Cornblatt BA. Predictors of remission, schizophrenia, and bipolar disorder in adolescents with brief psychotic disorder or psychotic disorder not otherwise specified considered at very high risk for schizophrenia. Journal of Child & Adolescent Psychopharmacology. 18(5):475-90, 2008.
Leucht C. Kitzmantel M. Chua L. Kane J. Leucht S. Haloperidol versus chlorpromazine for treatment of schizophrenia. Schizophrenia Bulletin. 34(5):813-5, 2008
Correll CU, Frederickson AM, Kane JM, Manu P. Equally increased risk for metabolic syndrome in patients with bipolar disorder and schizophrenia treated with second-generation antipsychotics. Bipolar Disorders. 10(7):788-97, 2008
Shen J. Kobak KA. Zhao Y. Alexander MM, Kane JM. Use of remote centralized raters via live 2-way video in a multicenter clinical trial for schizophrenia. Journal of Clinical Psychopharmacology. 28(6):691-3, 2008.
Leucht S, Davis JM, Engel RR, Kissling W, Kane JM. Definitions of response and remission in schizophrenia: recommendations for their use and their presentation. Acta Psychiatrica Scandinavica, Supplementum. (438):7-14, 2009.
Goldberg TE. Burdick KE. McCormack J. Napolitano B. Patel RC. Sevy SM. Goldman R. Lencz T. Malhotra AK. Kane JM. Robinson DG. Lack of an inverse relationship between duration of untreated psychosis and cognitive function in first episode schizophrenia. Schizophrenia Research. 107(2-3):262-6, 2009.
Correll CU, Frederickson AM, Figen V, Ginn-Scott EJ, Pantaleaon Moya RA, Kane JM, Manu P. The QTc interval and its dispersion in patients receiving two atypical antipsychotics: a matched case-control study. Eur Arch Psychiatry Clin Neurosci 259(1):23-7, 2009.